



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 17/00 (2006.01)
A61K 9/08 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2024/050573

(22) International Filing Date:

09 October 2024 (09.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/543,215	09 October 2023 (09.10.2023)	US
63/543,245	09 October 2023 (09.10.2023)	US
63/604,178	29 November 2023 (29.11.2023)	US
63/555,780	20 February 2024 (20.02.2024)	US
63/556,342	21 February 2024 (21.02.2024)	US
63/645,820	10 May 2024 (10.05.2024)	US
63/645,821	10 May 2024 (10.05.2024)	US
63/649,158	17 May 2024 (17.05.2024)	US
63/649,229	17 May 2024 (17.05.2024)	US
63/659,293	12 June 2024 (12.06.2024)	US
63/659,296	12 June 2024 (12.06.2024)	US

(71) Applicant: JASPER THERAPEUTICS, INC. [US/US];
2200 Bridge Parkway, Suite 102, Redwood City, California
94065 (US).


(72) Inventors: PANG, Wendy; 1612 California Ave., Palo Alto, California 94306 (US). KWON, Hye-Sook; 901 Ocean View Ave., San Mateo, California 94401 (US). CHANG, Charles Alen; 605 San Conrado Terrace, Unit 1, Sunnyvale, California 94085 (US). YU, Mang; 2255 Showers Dr., APT 392, Mountain View, California 94040 (US). ADELMAN, Daniel Chazan; c/o Jasper Therapeutics, Inc., 2200 Bridge Parkway, Suite 102, Redwood City, California 94065 (US). TUCKER, Edwin; c/o Jasper Therapeutics, Inc., 2200 Bridge Parkway, Suite 102, Redwood City, California 94065 (US).

(74) Agent: LAHERTY, Carol et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: COMPOSITIONS AND METHODS FOR DEPLETION OF MAST CELLS

FIG. 19E



(57) Abstract: Provided herein are compositions and methods related to depletion of mast cells using an anti-c-kit antibody. The compositions and methods described herein may be used to treat a subject in need of mast cell depletion due to a variety of diseases or disorders, such as chronic spontaneous urticaria (CSU).

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*